What Is an Embryologist? – Newswise – Newswise (press release)

Nicole Burns and Melissa Nanidzhanyan, Embryologists, The Valley Hospital Fertility Center

Newswise If you or a loved one is having difficulty conceiving, you may have researched in vitro fertilization options. In vitro fertilization, which is commonly referred to as IVF, is a process that begins with ovulation induction to stimulate a womans ovaries. Next, the eggs are harvested through an ultrasound-guided technique. Once the eggs have been retrieved, they are fertilized and grown in a laboratory for three to five days before the embryos are transferred into the womans uterus or frozen for implantation at a later date.

A key member of an IVF patients clinical team is her embryologist. An embryologist is a scientist who has a bachelors degree in the clinical sciences and who participates in continuing education to ensure that she is aware of any clinical developments in the field of embryology. She specializes in the care of embryos from the time of egg retrieval to the time when the embryo is implanted into the womans uterus. The embryologist is responsible for:

As an IVF patient, there are two different embryo cycles that may be involved in your care. The first, a fresh cycle, involves the embryologist inseminating the egg so that an embryo can be implanted into the patients uterus five days after the eggs retrieval. The second cycle is called the frozen cycle. In the frozen cycle, the embryologist creates the embryos and freezes them rather than implanting them. The patient will return to the office approximately a month later to have the embryo implanted into her uterus.

If the embryos require genetic testing, five cells are gathered from the embryo on day five or six after insemination. The cells are then sent to a specialized lab for genetic testing, which can take approximately a week. While the cells are undergoing genetic testing, the embryologists will closely examine the embryos to identify those that are morphologically strongest. This includes testing all 23 chromosomes for any visible abnormalities. Because of the length of time involved in these additional steps, the patients are generally completing a frozen cycle rather than a fresh cycle. However, for certain patients, this extra testing can increase the chance of a successful pregnancy by reducing instances of miscarriages.

Continued here:
What Is an Embryologist? - Newswise - Newswise (press release)

In Breakthrough, Scientists Edit a Dangerous Mutation From Genes in Human Embryos – New York Times

Weve always said in the past gene editing shouldnt be done, mostly because it couldnt be done safely, said Richard Hynes, a cancer researcher at the Massachusetts Institute of Technology who co-led the committee. Thats still true, but now it looks like its going to be done safely soon, he said, adding that the research is a big breakthrough.

What our report said was, once the technical hurdles are cleared, then there will be societal issues that have to be considered and discussions that are going to have to happen. Nows the time.

Scientists at Oregon Health and Science University, with colleagues in California, China and South Korea, reported that they repaired dozens of embryos, fixing a mutation that causes a common heart condition that can lead to sudden death later in life.

Scientists tried two techniques to remove a dangerous mutation. In the first, genetic scissors were inserted into fertilized eggs. The mutation was repaired in some of the resulting embryos but not always in every cell. The second method worked better: By injecting the scissors along with the sperm into the egg, more embryos emerged with repaired genes in every cell.

When gene-editing components were introduced into a fertilized egg, some embryos contained a patchwork of repaired and unrepaired cells.

Gene-editing

components inserted

after fertilization

Cell with

unrepaired

gene

Mosaicism in

later-stage embryo

When gene-editing components were introduced with sperm to the egg before fertilization, more embryos had repaired mutations in every cell.

Gene-editing components

inserted together with sperm,

before fertilization

In 42 of 58

embryos

tested, all

cells were

repaired

Uniform

later-stage embryo

When gene-editing components were introduced into a fertilized egg, some embryos contained a patchwork of repaired and unrepaired cells.

Gene-editing

components inserted

after fertilization

Cell with

unrepaired

gene

Mosaicism in

later-stage embryo

When gene-editing components were introduced with sperm to the egg before fertilization, more embryos had repaired mutations in every cell.

Gene-editing

components inserted

together with sperm,

before fertilization

In 42 of 58

embryos

tested, all

cells were

repaired

Uniform

later-stage embryo

If embryos with the repaired mutation were allowed to develop into babies, they would not only be disease-free but also would not transmit the disease to descendants.

The researchers averted two important safety problems: They produced embryos in which all cells not just some were mutation-free, and they avoided creating unwanted extra mutations.

It feels a bit like a one small step for (hu)mans, one giant leap for (hu)mankind moment, Jennifer Doudna, a biochemist who helped discover the gene-editing method used, called CRISPR-Cas9, said in an email.

I expect these results will be encouraging to those who hope to use human embryo editing for either research or eventual clinical purposes, said Dr. Doudna, who was not involved in the study.

Much more research is needed before the method could be tested in clinical trials, currently impermissible under federal law. But if the technique is found to work safely with this and other mutations, it might help some couples who could not otherwise have healthy children.

Potentially, it could apply to any of more than 10,000 conditions caused by specific inherited mutations. Researchers and experts said those might include breast and ovarian cancer linked to BRCA mutations, as well as diseases like Huntingtons, Tay-Sachs, beta thalassemia, and even sickle cell anemia, cystic fibrosis or some cases of early-onset Alzheimers.

You could certainly help families who have been blighted by a horrible genetic disease, said Robin Lovell-Badge, a professor of genetics and embryology at the Francis Crick Institute in London, who was not involved in the study.

You could quite imagine that in the future the demand would increase. Maybe it will still be small, but for those individuals it will be very important.

The researchers also discovered something unexpected: a previously unknown way that embryos repair themselves.

In other cells in the body, the editing process is carried out by genes that copy a DNA template introduced by scientists. In these embryos, the sperm cells mutant gene ignored that template and instead copied the healthy DNA sequence from the egg cell.

We were so surprised that we just couldnt get this template that we made to be used, said Shoukhrat Mitalipov, director of the Center for Embryonic Cell and Gene Therapy at Oregon Health and Science University and senior author of the study. It was very new and unusual.

The research significantly improves upon previous efforts. In three sets of experiments in China since 2015, researchers seldom managed to get the intended change into embryonic genes.

And some embryos had cells that did not get repaired a phenomenon called mosaicism that could result in the mutation being passed on as well as unplanned mutations that could cause other health problems.

In February, a National Academy of Sciences, Engineering and Medicine committee endorsed modifying embryos, but only to correct mutations that cause a serious disease or condition and when no reasonable alternatives exist.

Sheldon Krimsky, a bioethicist at Tufts University, said the main uncertainty about the new technique was whether reasonable alternatives to gene editing already exist.

As the authors themselves noted, many couples use pre-implantation genetic diagnosis to screen embryos at fertility clinics, allowing only healthy ones to be implanted. For these parents, gene editing could help by repairing mutant embryos so that more disease-free embryos would be available for implantation.

Hank Greely, director of the Center for Law and the Biosciences at Stanford, said creating fewer defective embryos also would reduce the number discarded by fertility clinics, which some people oppose.

The larger issue is so-called germline engineering, which refers to changes made to embryo that are inheritable.

A new technique known as Crispr has revolutionized humans ability to edit DNA. See if you can identify whether a given development has already happened, could eventually happen or is pure fiction.

If youre in one camp, its a horror to be avoided, and if youre in the other camp, its desirable, Dr. Greely said. Thats going to continue to be the fight, whether its a feature or a bug.

For now, the fight is theoretical. Congress has barred the Food and Drug Administration from considering clinical trials involving germline engineering. And the National Institutes of Health is prohibited from funding gene-editing research in human embryos. (The new study was funded by Oregon Health and Science University, the Institute for Basic Science in South Korea, and several foundations.)

The authors say they hope that once the method is optimized and studied with other mutations, officials in the United States or another country will allow regulated clinical trials.

I think it could be widely used, if its proven safe, said Dr. Paula Amato, a co-author of the study and reproductive endocrinologist at O.H.S.U. Besides creating more healthy embryos for in vitro fertilization, she said, it could be used when screening embryos is not an option or to reduce arduous IVF cycles for women.

Dr. Mitalipov has pushed the scientific envelope before, generating ethical controversy with a so-called three-parent baby procedure that would place the nucleus of the egg of a woman with defective cellular mitochondria into the egg from a healthy woman. The F.D.A. has not approved trials of the method, but Britain may begin one soon.

The new study involves hypertrophic cardiomyopathy, a disease affecting about one in 500 people, which can cause sudden heart failure, often in young athletes.

It is caused by a mutation in a gene called MYBPC3. If one parent has a mutated copy, there is a 50 percent chance of passing the disease to children.

Using sperm from a man with hypertrophic cardiomyopathy and eggs from 12 healthy women, the researchers created fertilized eggs. Injecting CRISPR-Cas9, which works as a genetic scissors, they snipped out the mutated DNA sequence on the male MYBPC3 gene.

They injected a synthetic healthy DNA sequence into the fertilized egg, expecting that the male genome would copy that sequence into the cut portion. That is how this gene-editing process works in other cells in the body, and in mouse embryos, Dr. Mitalipov said.

Instead, the male gene copied the healthy sequence from the female gene. The authors dont know why it happened.

Maybe human sex cells or gametes evolved to repair themselves because they are the only cells that transmit genes to offspring and need special protection, said Juan Carlos Izpisua Belmonte, a co-author and geneticist at the Salk Institute.

Out of 54 embryos, 36 emerged mutation-free, a significant improvement over natural circumstances in which about half would not have the mutation. Another 13 embryos also emerged without the mutation, but not in every cell.

The researchers tried to eliminate the problem by acting at an earlier stage, injecting the egg with the sperm and CRISPR-Cas9 simultaneously, instead of waiting to inject CRISPR-Cas9 into the already fertilized egg.

That resulted in 42 of 58 embryos, 72 percent, with two mutation-free copies of the gene in every cell. They also found no unwanted mutations in the embryos, which were destroyed after about three days.

The method was not perfect. The remaining 16 embryos had unwanted additions or deletions of DNA. Dr. Mitalipov said he believed fine-tuning the process would make at least 90 percent of embryos mutation-free.

And for disease-causing mutations on maternal genes, the same process should occur, with the fathers healthy genetic sequence being copied, he said.

But the technique will not work if both parents have two defective copies. Then, scientists would have to determine how to coax one gene to copy a synthetic DNA sequence, Dr. Mitalipov said.

Otherwise, he said, it should work with many diseases, a variety of different heritable mutations.

R. Alta Charo, a bioethicist at University of Wisconsin at Madison, who led the committee with Dr. Hynes, said the new discovery could also yield more information about causes of infertility and miscarriages.

She doubts a flood of couples will have edited children.

Nobodys going to do this for trivial reasons, Dr. Charo said. Sex is cheaper and its more fun than IVF, so unless youve got a real need, youre not going to use it.

Excerpt from:
In Breakthrough, Scientists Edit a Dangerous Mutation From Genes in Human Embryos - New York Times

Two genes help older brain gain new cells – Yale News

Two genes act as molecular midwives to the birth of neurons in adult mammals and when inactivated in mice cause symptoms of Fragile X Syndrome, a major cause of mental retardation, a new Yale University study has shown.

In humans as well as mice, most neurons are created prior to birth and few new brain cells are produced as adults. The new study identified two genes that are crucial to creation of neurons in the brain region responsible for learning and memory. When the two Pumilio genes PUM1 and PUM2 are knocked out in mice, few neural stem cells are created in this region, which becomes very small. The mice can no longer navigate mazes and exhibit the same pathology as humans with Fragile X Syndrome.

The genes control whether RNA that has already been transcribed actually go on to create proteins, a little studied step of gene regulation with major biological implications, said senior author Haifan Lin, the Eugene Higgins Professor of Cell Biology, and professor of genetics and of obstetrics, gynecology, and reproductive sciences as well as director of the Yale Stem Cell Center.

Meng Zhang, a graduate student in the Lin lab, was lead author of the study published Aug. 15 in the journal Genes & Development.

More here:
Two genes help older brain gain new cells - Yale News

Gene Involved in Natural Variation in Heart Regeneration Identified – Technology Networks

Some people are better than others at recovering from a wounded heart, according to a new USC Stem Cell study published in Nature Genetics.

In the study, first author Michaela Patterson, a postdoctoral fellow in the laboratory of Henry Sucov, and her colleagues focused on a regenerative type of heart muscle cell called a mononuclear diploid cardiomyocyte (MNDCM). Zebrafish and newborn mammals, including mice and humans, have large numbers of MNDCMs and a relatively robust ability to regenerate heart muscle. However, adult mammals have few MNDCMs and a correspondingly limited capacity for regeneration after an injury such as a heart attack.

Even so, the situation for adult mammals is not uniformly dire: Patterson and her co-authors observed a surprising amount variation in the number of MNDCMs among different strains of adult mice. In some strains, MNDCMs accounted for only 1.9 percent of heart muscle cells. In others, a full 10 percent were MNDCMs. As expected, the higher the percentage of MNDCMs, the better the mice fared in regenerating their heart muscle after injury.

This was an exciting finding, said Patterson. It suggests that not all individuals are destined to permanent heart muscle loss after a heart attack, but rather some can naturally recover both heart muscle mass and function. If we can identify the genes that make some individuals better at it than others, then perhaps we can stimulate regeneration across the board.

Using an approach called a genome-wide association study, the researchers indeed identified one of the key genes underlying this variation: Tnni3k. By blocking this gene in mice, the researchers produced higher percentages of MNDCMs and enhanced heart regeneration. In contrast, activating this gene in zebrafish decreased MNDCMs and impaired heart regeneration.

Sucovsenior author and professor of stem cell biology and regenerative medicine, integrative anatomical sciences, and biochemistry and molecular biologydescribed how this early discovery could be a first step towards a preventive strategy to mitigate heart disease, the leading cause of death in the Western world.

The activity of this gene, Tnni3k, can be modulated by small molecules, which could be developed into prescription drugs in the future, he said. These small molecules could change the composition of the heart over time to contain more of these regenerative cells. This could improve the potential for regeneration in adult hearts, as a preventative strategy for those who may be at risk for heart failure.

This article has been republished frommaterialsprovided by the University of Southern California. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference:

Patterson, M., Barske, L., Handel, B. V., Rau, C. D., Gan, P., Sharma, A., . . . Sucov, H. M. (2017). Frequency of mononuclear diploid cardiomyocytes underlies natural variation in heart regeneration. Nature Genetics. doi:10.1038/ng.3929

Continued here:
Gene Involved in Natural Variation in Heart Regeneration Identified - Technology Networks

New science building comes with $150K energy savings – Chicago Tribune

The newest building on the Valparaiso University campus was designed with safety and energy savings in mind.

The Center for the Sciences: Chemistry and Biochemistry offers 54,000 square feet and a massive air handling system meant to keep students and professors safe while they work in the lab, with enough energy efficiency bonus points to earn a rebate from NIPSCO of almost $150,000.

"It's almost completely lab space," said physics professor Andrew Richter, co-chair of the building committee, Tuesday.

The structure features large glass windows; science-themed photo montage artwork in the stairwells put together by students; and a glass sculpture hanging in the two-story foyer designed by Hot Shop, a glass blowing studio in Valparaiso.

The building also includes "lots of student space and tons of ways for students to gather together," Richter said.

But it's the building's energy efficiency that garnered a rebate of $148,765 from NIPSCO's Business Energy Efficiency Program.

"With a building that exchanges air so often, the basement looks like the engine room of an aircraft carrier. You could just bleed money in energy in a building like this," Richter said.

The university, he said, needed a facility that was up to air handling standards for safety because of all of the chemicals and other matter being used in the building's multiple labs, many of which were located in the Neils Science Center.

The Center for the Sciences has LED lighting; energy recovery in its air handling units; and variable volume air handlers that "respond to demand in the building," said Jason Kutch, the university's energy manager and facilities engineer.

Kutch was charged with seeing where the building stood in meeting baseline safety standards, and applying for NIPSCO's incentive program.

Most of the energy savings are derived from meeting the state's energy code, which dates back to 2007, said Byran Zichel, a field manager for Lockheed Martin Energy, which manages NIPSCO's program.

The program has different categories, including one for new construction, which is where the Center of the Sciences qualified.

In total, the university said the construction project saved 954,533 kilowatt hours and 80,861 therm. Just one of them is the equivalent energy output of burning roughly 100 cubic feet of natural gas.

"Really, the goal is anything and everything that saves energy, NIPSCO is willing to take a look at," Zichel said.

Amy Lavalley is a freelance reporter for the Post-Tribune.

View post:
New science building comes with $150K energy savings - Chicago Tribune

Study of Vitamin D Receptor Gene Polymorphism (FokI, TaqI and ApaI) Among Prostate Cancer Patients in North India. – UroToday

Incidence of prostate cancer is rising worldwide. Multiple factors have been suggested for the aetiology of prostate cancer including ethnic, genetic and diet. Vitamin D (calcitriol) has been shown to have role in cell growth and differentiation and its deficiency is implicated as one of the aetiological factors in prostate cancer. Prostatic epithelial cells express Vitamin D Receptor (VDR) as well as 1- hydroxylase enzyme that are required for the synthesis of calcitriol and its action. Polymorphism in VDR gene has been associated with prostate cancer in some epidemiological studies; but, there is paucity of information in the Indian context.

The present study was aimed to explore the association of VDR gene polymorphism with the development of prostate cancer.

Three Single Nucleotide Polymorphisms (SNP) sites viz., FokI, TaqI and ApaI were analysed in 120 cases of prostate cancer which were compared with their 120 healthy first degree relatives and 120 non-related controls in the Department of Biochemistry in collaboration with the Department of Urology.

Analysis showed significantly decreased incidence of Tt and Aa genotype in prostate cancer patients as compared to healthy non-relative controls (p=0.016 and 0.043 respectively). As compared to first degree relatives, incidence of Tt genotype is significantly lower in cases (p=0.005). No significant association was found with FokI polymorphism.

This study suggests the protective role of heterozygous genotypes of TaqI and ApaI polymorphism against the development of prostate cancer.

Journal of clinical and diagnostic research : JCDR. 2017 Jun 01 [Epub]

Pankaj Ramrao Kambale, Deepa Haldar, B C Kabi, Kalpana Pankaj Kambale

Assistant Professor, Department of Biochemistry, S.M.B.T. Institute of Medical Sciences and Research Centre, Nashik, Maharashtra, India., Senior Resident, Department of Biochemistry, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India., Professor Director, Department of Biochemistry, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India., Senior Lecturer, Department of Periodontology, S.M.B.T. Institute of Dental Sciences and Research, Nasik, Maharashtra, India.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/28764147

Go here to read the rest:
Study of Vitamin D Receptor Gene Polymorphism (FokI, TaqI and ApaI) Among Prostate Cancer Patients in North India. - UroToday

Chancellor Recognizes Powe Awardees Jagadamma, McCord – Tennessee Today

UTs Sindhu Jagadamma and Rachel Patton McCord are recipients ofthe 2017 Ralph E. Powe Junior Faculty Enhancement Award from Oak Ridge Associated Universities (ORAU).

Chancellor Beverly Davenport recently presented plaques to Jagadamma, assistant professor of biosystems engineering and soil science in the UT Institute of Agriculture, and McCord, assistant professor of biochemistry and cellular and molecular biology, in recognition of the honor.

Often funding agencies require extensive preliminary data, effectively asking that a project be halfway done before funding it, said McCord.This can make things difficult for junior faculty who are just getting projects off the ground, but early support like this Powe Award can give projects momentum to be more competitive for extensive funding later.

From left, Julie Carrier, head of UTIAs biosystems engineering and soil science; Taylor Eighmy, vice chancellor for research and engagement; Sindhu Jagadamma; UT Chancellor Beverly Davenport; Rachel Patton McCord; Dan Roberts, head of the Department of Biochemistry and Cellular and Molecular Biology; and Theresa Lee, dean of the College of Arts and Sciences.

McCord will usethe award to measure the 3-D structure of chromosomes inside metastatic cancer cells as they squeeze through narrow spaces or are exposed to drug treatments that help prevent metastasis. She will collaborate with scientists at the Center for Nanophase Materials Sciences and the Joint Institute for Computational Sciences at Oak Ridge National Laboratory (ORNL), and will apply for additional funding from the American Cancer Society and the National Institutes of Health.

The expert peer review process of the Powe Award is extremely valuable, said McCord. The feedback I received on my project proposal will serve me well as we move forward with this project and future grants.

Jagadamma will use the award to support a graduate student who is assisting her on a collaborative project with Melanie Mayes at ORNL, aimed at understanding how soil moisture conditions constrain the microbial decomposition of organic carbon present in soil. The award will cover the cost of a weeklong training on techniques and tools to analyze microbial community data.

This award will help expand one of my current research focus areas and facilitate data collection that will help me to develop competitive grant proposals to the Department of Energy and National Science Foundation, said Jagadamma. The Powe Award will also enhance visibility of my research program, which is critical to initiate new research partnerships within and outside the University of Tennessee.

The Powe Awards provide seed money for research by junior faculty atORAU member institutions. They are intended to enrich the research and professional growth of young faculty and lead the way to additional funding opportunities. UTs Office of Research and Engagement matches the $5,000 award from ORAU.

Read more here:
Chancellor Recognizes Powe Awardees Jagadamma, McCord - Tennessee Today

New genes discovered regulating brain metastases in lung cancer – Medical Xpress

Mohini Singh is a PhD candidate in biochemistry at the Michael G. DeGroote School of Medicine at McMaster University Credit: McMaster University

Research from McMaster University has identified new regulators of brain metastases in patients with lung cancer.

These regulators are the genes called SPOCK1 and TWIST2.

The discovery was made by researchers at the Stem Cell and Cancer Research Institute at McMaster University and was recently published online in the journalActa Neuropathologica.

"Brain metastases are a secondary brain tumour, which means they are caused by cancer cells that escape from primary tumours like lung, breast or melanoma, and travel to the brain," said Mohini Singh, the study's primary author and a PhD candidate in biochemistry at the Michael G. DeGroote School of Medicine at McMaster.

"We set out to find which genes can regulate the cells that initiate brain metastases, which we've termed brain metastasis initiating cells or BMICs. In other words, what are the genes that are sending the signal to these lung BMICs to leave the lung tumour, go into the blood stream, invade the blood-brain barrier and form a tumour in the brain."

The study used samples from lung cancer patients with brain metastases. The samples were incubated to enrich for BMICs, then injected into the lungs, hearts and brains of mice. The subsequent development of brain metastases was studied by researchers.

"If you look at a set of lung cancer patients, like we did in the paper, who develop brain metastases, they all have those two genes in their primary lung cancer," said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hospital.

"Patients who don't get brain metastases don't have these genes in their primary lung cancer."

Brain metastases are the most common brain tumour in adults and are a leading cause of death in cancer patients.

"If you can identify the genes that cause metastases, then you can determine a predictive model and you can work towards blocking those genes with possible treatments," said Mohini Singh.

Explore further: Preventing the development of brain tumours

Read the original:
New genes discovered regulating brain metastases in lung cancer - Medical Xpress

Dr. Jerome Adams confirmed as surgeon general – CNN

"To be confirmed as the 20th US Surgeon General is truly an indescribable honor," Adams tweeted Thursday.Adams is an anesthesiologist who previously served as the Indiana state health commissioner -- "in essence the Surgeon General for Indiana," he said in a statement to the Senate committee. Prior to that, he served as a staff anesthesiologist and assistant professor of anesthesia at the Indiana University School of Medicine, where he completed his medical degree. He earned undergraduate degrees in biochemistry and biopsychology and a master's degree in public health."The addictive properties of prescription opioids is a scourge in America and it must be stopped," wrote Adams in his nomination committee statement. He added that he shared US Health and Human Services Secretary Tom Price's top priorities, including "the opioid epidemic, and untreated mental illness, which lie at the root of much of the current situation." "I bring to this discussion a unique perspective, and a proven track record of bringing together various groups to address the problem," Adams wrote in his statement. In May 2015, he revealed that his brother is an addict during testimony at a House Energy and Commerce Committee.

That same year, Adams dealt with the lasting effects of drug use as health commissioner. Two-hundred nineteen people were infected with HIV in Southeast Indiana as a result of injecting the prescription opioid Opana. A needle exchange program was put into place to slow the outbreak.

Adams also vowed to make "wellness and community and employer engagement a centerpiece of my agenda." He said the opioid epidemic, obesity, healthcare access and cost will not be successfully tackled if the nation continues to focus on handling these problems only "after they've taken hold."

"Many people call the US Surgeon General the nation's 'Top Doctor,' " Adams wrote in his statement. He said the moniker doesn't do justice to the many professions within the Health Corps, including nurses, pharmacists, therapists and scientists, and insinuates that one person can be "all things to health" -- but doesn't give "proper consideration to the vital role partnerships play."Adams tweeted: "The wonderful people of Indiana trusted and supported me, and ultimately this appointment is about what we've all accomplished together."

Adams noted at his hearing that he is a father to three children, ages 7, 11 and 13 years old.

"When making decisions, I literally have no choice but to think about both the immediate impact on our nation's children -- my own children included -- and the world I am leaving for future generations," he said at that time.

"I hope to make America healthier," wrote Adams in his statement. "Healthy people and communities are more productive, and profitable, and in turn attract more jobs and prosperity."

More:
Dr. Jerome Adams confirmed as surgeon general - CNN

HumanZyme Announces Human Cell-Expressed Interferon beta for Immunology and Immunotherapy Research … – Benzinga

HumanZyme Inc. announces the launch of recombinant human Interferon beta expressed from HEK293 cells for research purposes. HumanZyme's HumanKine IFN beta has native processing, glycosylation and folding, preserving its biologic function and activity. HumanZyme's HumanKine proteins are animal product-free, xeno-free and carrier-free.

Chicago, IL (PRWEB) August 08, 2017

HumanZyme Inc., a leading supplier of novel recombinant human proteins and growth factors expressed in human cells, today announced the launch of HumanKine Interferon beta (IFN beta) expressed from HEK293 cells. IFN beta isa member of the type I family of interferonsthat activate Th1-type innate immune responses against viral and bacterial infection, and have antiproliferative and immunomodulatory functions.IFN beta is currently FDA-approved in injectable form as a treatment for multiple sclerosis, an autoimmune disease, and has been investigated for use in cancer therapeutics for its anti-tumor activity.

According to Scott Coleridge, CEO at HumanZyme, "We are proud to be the only commercial supplier of high-quality, tag-free recombinant human Interferon beta expressed in human cells for research purposes. Our proprietary HEK293 expression system allows us to express difficult proteins in a human cell line to provide the most authentic recombinant products possible. The new IFN beta further expands our animal component-free HumanKine product line, and the product is priced competitively and also available in bulk."

Glycosylation of the IFN beta protein by a single asparagine-linked sugar chain is essential to its activity and stability, both in vitro and in vivo. IFN beta purified from human cells has been shown to have the highest biologic activity and stability compared to recombinant human IFN beta produced in non-human expression systems. HumanZyme's recombinant human IFN beta expressed in human cells assures native processing, glycosylation and folding of the purified protein compared to bacterial, mammalian cell lines, or insect cell expression systems, preserving its biologic function and activity. HumanZyme's HumanKine proteins are also animal-derived product free, xeno-free and carrier-free.

For more information, see our Interferon beta product page.

About HumanZyme, Inc.:HumanZyme, Inc. is the global leader in providing highly authentic recombinant human proteins from human cells. Our process is cost-effective and scalable making our proteins suitable for the research, diagnostic, drug discovery and biopharmaceutical markets. HumanZyme leverages its proprietary engineered human cells, expression vector, and cell culture media to ensure high-yield production of recombinant proteins with native human post-translational modifications. We are a leading provider of cytokines and growth factors and a preferred outsourcing supplier of human protein production. Our products and services support a broad range of customers worldwide, from academic and government research institutions to biotechnology and pharmaceutical companies.

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/08/prweb14577825.htm

View original post here:
HumanZyme Announces Human Cell-Expressed Interferon beta for Immunology and Immunotherapy Research ... - Benzinga